Skip to main content
. Author manuscript; available in PMC: 2020 Sep 1.
Published in final edited form as: Clin Cancer Res. 2019 Dec 18;26(5):1094–1104. doi: 10.1158/1078-0432.CCR-19-0909

Figure 3: Integrated genomic characterization of 83 PDX lines.

Figure 3:

Mutations and copy number variants (CNVs) from WES are shown for core glioma genetic drivers. When available (n=55), patient germline variants were subtracted. Molecular gene expression subtype was determined from RNAseq (14). DNA methylation group was determined from genome wide methylation profiling according to TCGA pan-glioma classification (15). MGMT promoter methylation was assessed by quantitative methylation-specific PCR performed at Mayo Clinic. TERT promoter mutations (C228T and C250T) were detected by Sanger sequencing.